文献速递心境障碍

精神药物与双相障碍皮质下脑体积交互的ENIGMA mega分析

Psychotropic medications and their interactions with subcortical brain volume in bipolar disorder: An ENIGMA mega-analysis.
PubMed 文献 · Mol Psychiatry · 2026-01-15

该研究基于ENIGMA双相障碍工作组34个研究组汇总的2664例双相障碍患者和4065名对照,采用mega分析评估精神药物状态与皮质下脑体积的关联,并探索药物间交互作用。结果显示用药患者皮质下体积更小、脑室更大,抗癫痫药和抗精神病药与海马及丘脑体积减小相关,而合并锂盐可减弱抗癫痫药与海马体积的负相关。

要点

  • 未用药双相障碍患者仅见轻度脑室扩大和壳核体积增大。
  • 使用精神药物者皮质下体积更小、脑室更大,效应量较小。
  • 合并锂盐可减弱抗癫痫药与海马体积减小的负相关。

核心结论

  • 精神药物状态与双相障碍患者皮质下脑体积改变相关,NbN分类有助于未来研究。

研究设计与样本

  • ENIGMA双相障碍工作组mega分析,汇总34个研究组2664例患者和4065名对照的MRI数据。
  • 采用标准化ENIGMA协议测量皮质下脑体积,线性混合效应回归评估药物与体积关联,并做调节分析。

主要发现

  • 未用药患者(n=410)较对照见轻度脑室扩大(d=0.07)和壳核体积增大(d=0.06)。
  • 用药患者皮质下体积更小(d=-0.06至-0.11)、脑室更大(d=0.11至0.19)。
  • 抗癫痫药和抗精神病药使用与海马及丘脑体积减小相关(d=-0.07至-0.14)。
  • NbN分类中「丙戊酸盐」和「多巴胺及其他单胺受体拮抗剂」是双相障碍与对照体积差异的关键变量。
  • 合并锂盐减弱抗癫痫药与海马体积的负相关(β=0.19,q=0.038)。

关键数值与推荐

  • 药物状态按综合征分类和神经科学基础命名(NbN)分类记录。
  • 效应量以Cohen d表示,交互分析报告β=0.19、q=0.038。

临床怎么用

  • 解读双相障碍患者脑结构MRI时需考虑当前精神药物状态。
  • 锂盐与抗癫痫药联用可能减轻抗癫痫药相关的海马体积减小。

局限性

  • 横断面设计无法推断药物与脑体积改变的因果关系。
  • 原文未报告纵向随访数据,需未来综合纵向研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MRI studies in bipolar disorder (BD) have yielded inconsistent findings, partly due to the varied use of psychotropic medications. This study utilised a mega-analysis approach, accounting for concurrent medication status (syndrome-based and Neuroscience-based Nomenclature (NbN) classifications), in order to assess the association of medication status with subcortical brain volumes in BD. Data from 2,664 BD patients and 4,065 controls (CN) were pooled from 34 research groups as part of the ENIGMA Bipolar Disorder Working Group. Standardized ENIGMA protocols were used to measure subcortical brain volumes. Linear-mixed-effects regression evaluated the association between psychotropic medications and subcortical volumes, and moderation analyses explored interactions. Medication-free patients (n = 410) showed mild ventricular enlargement (d = 0.07) and increased putamen volume (d = 0.06) compared to CN. Patients taking psychotropic medications exhibited smaller subcortical volumes (d = -0.06 to -0.11) and larger ventricles (d = 0.11 to 0.19). Use of antiepileptic and antipsychotic medications was associated with smaller hippocampal and thalamic volumes (d = -0.07 to -0.14), while NbN classification indicated that the categories of 'valproate' and 'dopamine and other monoamine receptor antagonists' are key variables when considering volume differences between BD and CN. Concurrent lithium use weakened the negative association between antiepileptic use and hippocampal volume (β = 0.19, q = 0.038) in patients. Medication status is associated with altered subcortical brain volumes in BD. The NbN classification provides a useful framework for future studies, emphasizing the need for comprehensive longitudinal research to further unravel complex clinical-pharmacological-neurobiological interactions in BD.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. King S, O'Connor J, Corley E, et al. Psychotropic medications and their interactions with subcortical brain volume in bipolar disorder: An ENIGMA mega-analysis. Mol Psychiatry. 2026. PMID: 41540091. doi:10.1038/s41380-025-03432-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。